Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Feb
20
Today In Oncology
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo